In CRC, the combination of PD-1 inhibitor nivolumab, with or without ipilimumab, has demonstrated promising response rates and improved survival outcomes in patients with mismatch repair deficiency (dMMR) or high levels of MSI-H metastatic CRC [41, 42]. This evidence concerns the gene PDCD1 and mismatch repair cancer syndrome 1.